ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

Japan asks US for stable remdesivir supply as Tokyo rushes approval

Treatment could be available as early as mid-May

Japanese Prime Minister Shinzo Abe, left, and U.S. President Donald Trump: The Japanese government is trying to ensure supplies of the antiviral drug remdesivir to treat the coronavirus.    © Reuters

TOKYO -- Japan aims to approve remdesivir as a treatment for the coronavirus in as little as a week, the health minister said Saturday, as Tokyo asked the U.S. to ensure it receives adequate supplies of the drug.

The moves follow emergency U.S. approval of remdesivir, developed by Gilead Sciences, on Friday. Japan's expedited authorization procedures allow reporting of domestic clinical trials to be postponed to a later date, meaning the antiviral drug could be approved by mid-May.

"Gilead Sciences will file for approval [in Japan] within days," Health Minister Katsunobu Kato said at a news conference. "I issued a directive so we will be able to approve it within a week or so."

The streamlined process is allowed in cases where a drug has been approved for use overseas.

Remdesivir, originally developed as a treatment for Ebola by U.S. drugmaker Gilead, has gained global attention as a candidate treatment for people with severe COVID-19 symptoms.

Tokyo has asked Washington for a steady supply of remdesivir. There are concerns in the government over supplies, and that the U.S. may lack sufficient capacity to ensure Japan gets the medicine it needs. The government hopes to work with its counterparts in Washington to smooth procurement.

According to Japanese officials, the two countries have discussed ways to secure the drug ahead of the drug's approval in Japan. So far, there has been no clear response from the U.S. Some officials have expressed concern that even if remdesivir is approved, most of the drug will go to the U.S., slowing delivery of the antiviral to Japan.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more